Not Just Antibiotics: Is Cancer Chemotherapy Driving Antimicrobial Resistance?

Trends Microbiol. 2018 May;26(5):393-400. doi: 10.1016/j.tim.2017.10.009. Epub 2017 Nov 13.

Abstract

The global spread of antibiotic-resistant pathogens threatens to increase the mortality of cancer patients significantly. We propose that chemotherapy contributes to the emergence of antibiotic-resistant bacteria within the gut and, in combination with antibiotics, drives pathogen overgrowth and translocation into the bloodstream. In our model, these processes are mediated by the effects of chemotherapy on bacterial mutagenesis and horizontal gene transfer, the disruption of commensal gut microbiology, and alterations to host physiology. Clinically, this model manifests as a cycle of recurrent sepsis, with each episode involving ever more resistant organisms and requiring increasingly broad-spectrum antimicrobial therapy. Therapies that restore the gut microbiota following chemotherapy or antibiotics could provide a means to break this cycle of infection and treatment failure.

Keywords: intestinal dysbiosis; multiresistant organisms; mutation; sepsis.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Antineoplastic Agents / pharmacology*
  • Bacteria / drug effects
  • Bacteria / genetics
  • DNA Damage
  • Drug Combinations
  • Drug Resistance, Bacterial / drug effects*
  • Drug Resistance, Bacterial / genetics
  • Dysbiosis / microbiology
  • Gastrointestinal Microbiome / drug effects
  • Gene Transfer, Horizontal
  • Humans
  • Mutagenesis
  • Neoplasms / complications
  • Neoplasms / drug therapy
  • Sepsis / microbiology
  • Symbiosis / drug effects

Substances

  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Drug Combinations